MX2019012938A - Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. - Google Patents

Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.

Info

Publication number
MX2019012938A
MX2019012938A MX2019012938A MX2019012938A MX2019012938A MX 2019012938 A MX2019012938 A MX 2019012938A MX 2019012938 A MX2019012938 A MX 2019012938A MX 2019012938 A MX2019012938 A MX 2019012938A MX 2019012938 A MX2019012938 A MX 2019012938A
Authority
MX
Mexico
Prior art keywords
inhibitor
treating tumor
combined
preparing drug
ezh2
Prior art date
Application number
MX2019012938A
Other languages
English (en)
Inventor
Cao Guoqing
Zhang Lianshan
Ma Ke
Yang Changyong
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019012938A publication Critical patent/MX2019012938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se relaciona con el uso de un inhibidor de EZH2 combinado con un inhibidor de BTK en la preparación de un fármaco para tratar un tumor.
MX2019012938A 2017-05-18 2018-05-17 Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. MX2019012938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710350614 2017-05-18
PCT/CN2018/087246 WO2018210296A1 (zh) 2017-05-18 2018-05-17 一种ezh2抑制剂与btk抑制剂联合在制备***的药物中的用途

Publications (1)

Publication Number Publication Date
MX2019012938A true MX2019012938A (es) 2019-12-16

Family

ID=64273344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012938A MX2019012938A (es) 2017-05-18 2018-05-17 Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.

Country Status (12)

Country Link
US (1) US11065239B2 (es)
EP (1) EP3626239A4 (es)
JP (1) JP7125952B2 (es)
KR (1) KR102635949B1 (es)
CN (1) CN109937041B (es)
AU (1) AU2018269262B2 (es)
BR (1) BR112019023632A2 (es)
CA (1) CA3058241A1 (es)
MX (1) MX2019012938A (es)
RU (1) RU2762893C2 (es)
TW (1) TWI810185B (es)
WO (1) WO2018210296A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118277A1 (zh) * 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
WO2020117052A2 (en) * 2018-12-03 2020-06-11 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Ezh2- fgfr inhibition in cancer
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
CN110372562B (zh) 2019-07-09 2021-04-06 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的晶型及其制备方法
TW202114670A (zh) * 2019-09-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012223448B2 (en) * 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
RU2014117632A (ru) * 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения злокачественной опухоли
WO2013067300A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
SG11201507265XA (en) * 2013-04-08 2015-10-29 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
CN105873592B (zh) * 2013-12-06 2023-01-31 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP3122360B1 (en) 2014-03-25 2020-06-17 ONO Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
CA2953798C (en) * 2014-07-07 2019-06-11 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
US20160022684A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
SI3378859T1 (sl) 2015-11-19 2020-03-31 Jiangsu Hengrui Medicine Co., Ltd., Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini

Also Published As

Publication number Publication date
KR102635949B1 (ko) 2024-02-14
TWI810185B (zh) 2023-08-01
AU2018269262A1 (en) 2019-10-31
RU2019138222A3 (es) 2021-07-30
RU2762893C2 (ru) 2021-12-23
WO2018210296A1 (zh) 2018-11-22
RU2019138222A (ru) 2021-06-18
KR20200007851A (ko) 2020-01-22
JP2020519588A (ja) 2020-07-02
TW201900171A (zh) 2019-01-01
AU2018269262B2 (en) 2021-12-02
JP7125952B2 (ja) 2022-08-25
US11065239B2 (en) 2021-07-20
CN109937041B (zh) 2022-04-12
CA3058241A1 (en) 2018-11-22
US20210030736A1 (en) 2021-02-04
EP3626239A1 (en) 2020-03-25
EP3626239A4 (en) 2021-03-10
BR112019023632A2 (pt) 2020-08-18
CN109937041A (zh) 2019-06-25

Similar Documents

Publication Publication Date Title
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12019500135A1 (en) Methods of treating prostate cancer
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
IN2014MU00303A (es)
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
IN2014MU00495A (es)